Sanofi And Regeneron Pharmaceuticals' Dupixent Recommended For EU Approval By The CHMP To Treat COPD Patients
Portfolio Pulse from Benzinga Newsdesk
Sanofi and Regeneron Pharmaceuticals' Dupixent has been recommended for EU approval by the CHMP to treat COPD patients. This recommendation is based on Phase 3 trials showing significant benefits in reducing exacerbations and improving lung function. If approved, Dupixent would be the first targeted therapy for COPD in the EU and the first new treatment for the disease in over a decade.
May 31, 2024 | 6:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals' Dupixent has been recommended for EU approval to treat COPD, potentially becoming the first targeted therapy for this condition in the EU.
The recommendation for EU approval is a significant milestone for Regeneron, as it could lead to increased market share and revenue from Dupixent. The positive Phase 3 trial results further strengthen the case for approval.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Sanofi's Dupixent has been recommended for EU approval to treat COPD, potentially becoming the first targeted therapy for this condition in the EU.
The recommendation for EU approval is a significant milestone for Sanofi, as it could lead to increased market share and revenue from Dupixent. The positive Phase 3 trial results further strengthen the case for approval.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100